DBV Technologies

204 articles about DBV Technologies

• DBV Technologies to Present New Data at ACAAI 2023

  11/2/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced that new data on the use of Viaskin™ Peanut 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

• DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results

  10/31/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced the receipt of written feedback from the U.S. Food and Drug Administration regarding the remaining study design elements for the COMFORT supplemental safety studies.

• DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

  10/27/2023

  DBV Technologies announced that the Company will host a conference call and live audio webcast on Tuesday, October 31st, at 5:00 p.m. ET to review third quarter 2023 financial results and provide a business update.

• DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

  10/16/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023.

• DBV Technologies to Participate in Upcoming September 2023 Investor Conference

  9/5/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11th −13th in New York, NY.

• DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

  7/31/2023

  DBV Technologies announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT Toddlers and COMFORT Children supplemental safety studies in 1 – 3-year-olds and 4 – 7-year-olds, respectively, with a peanut allergy.

• DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

  7/25/2023

  DBV Technologies announced that the Company will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update.

• DBV Technologies to Participate in Upcoming EAACI Congress 2023

  6/8/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced upcoming participation in the European Academy of Allergy and Clinical Immunology Congress, June 9 – 11, 2023, in Hamburg, Germany.

• DBV Technologies to Participate in Upcoming June 2023 Investor Conference

  6/6/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference taking place on June 12th – 15th in Dana Point, CA.

• DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

  5/10/2023

  DBV Technologies announced that its Phase 3 EPITOPE trial of epicutaneous immunotherapy with Viaskin™ Peanut in children 1 – 3 years was published in the New England Journal of Medicine, reinforcing the potential of a new food allergy treatment option for this community.

• DBV Technologies to Participate in Upcoming May 2023 Investor Conference

  5/9/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the JMP Securities Life Sciences Conference taking place May 15-16 in New York, NY.

• DBV Technologies Reports First Quarter 2023 Financial Results

  5/4/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, reported financial results for the first quarter of 2023.

• DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

  4/19/2023

  DBV Technologies announced that DBV has received written responses from the U.S. Food and Drug Administration on the regulatory path for investigational Viaskin™ Peanut 250 μg patch in toddlers ages 1 – 3 years-old with a confirmed peanut allergy.

• DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

  4/12/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting.

• Ordinary and Extraordinary General Meeting of April 12, 2023

  3/24/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France.

• DBV Technologies Update

  3/13/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank.

• DBV Technologies Reports Full Year 2022 Financial Results and Business Update

  3/2/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, reported financial results for the full year 2022.

• DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

  3/2/2023

  DBV Technologies announces filing of 2022Annual Report on Form 10-K and 2022Universal Registration Document

• DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

  2/27/2023

  DBV Technologies announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update.

• DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

  2/21/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, announced upcoming participation at the American Academy of Allergy, Asthma, and Immunology Annual Scientific meeting, taking place February 24-27 in San Antonio, TX.